The chief executive of Netherlands-incorporated Mylan (Nasdaq: MYL) has defended the company’s pricing strategy on its EpiPen allergy injection.
Since acquiring the product in late 2007, the company has increased the price by more than 500%, prompting a public outcry. The injector now costs more than $600 for a two-pen pack.
Appearing before the US Senate's House Committee on Oversight and Government Reform in Washington this week, Heather Bresch insisted the price tag was misleading. She said it did not take into account discounts and rebates negotiated with health insurers and added that, after costs had been deducted, Mylan received a profit of just $100 per pack.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze